133001-95-3

Upstream product

• 6329-74-4 5-bromo-2-hydroxybenzamide 
• 77-76-9 2,2-dimethoxy-propane 
• 5485-91-6 2-acetoxy-5-bromo-benzoyl chloride 
• 1503-53-3 2-acetyloxy-5-bromobenzoic acid 
• 89-55-4 5-bromosalicyclic acid 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).

4-(pyridyl)- and 4-(oxo-pyridyl)-1,3-benzoxazines

Novel benzoxazine derivatives of the formula I STR1 wherein R1 to R5 have the meanings defined herein, and salts thereof, exhibit effects on the cardiovascular system.